Provided by Tiger Trade Technology Pte. Ltd.

Lantern Pharma Inc.

1.87
-0.0600-3.11%
Post-market: 1.940.0700+3.74%17:04 EDT
Volume:248.72K
Turnover:464.20K
Market Cap:23.86M
PE:-1.14
High:1.95
Open:1.87
Low:1.81
Close:1.93
52wk High:4.70
52wk Low:1.11
Shares:12.76M
Float Shares:10.14M
Volume Ratio:1.77
T/O Rate:2.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6362
EPS(LYR):-1.5709
ROE:-400.92%
ROA:-74.29%
PB:-7.42
PE(LYR):-1.19

Loading ...

Lantern Pharma Earnings Call: AI Spinout, Trial Momentum

TIPRANKS
·
Aug 25

Here's Why We're A Bit Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

Simply Wall St.
·
Aug 21

Lantern Pharma Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

Lantern Pharma Forms Open Medicine AI Subsidiary Business

TIPRANKS
·
Aug 14

Lantern Pharma Q2 EPS $(0.57) Misses $(0.38) Estimate

Benzinga Earnings
·
Aug 14

Lantern Pharma Q2 EPS USD -0.57

THOMSON REUTERS
·
Aug 14

Lantern Pharma Q2 FY26 Operating Loss Narrows 25% to $3.5 Million; Net Loss Widens to $7.1 Million

Reuters
·
Aug 14

Press Release: Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
Aug 14

Lantern Pharma Inc Expected to Post a Loss of 38 Cents a Share - Earnings Preview

Reuters
·
Aug 12

Lantern Pharma Inc Expected to Post a Loss of 38 Cents a Share - Earnings Preview

Reuters
·
Aug 07

Lantern Pharma Schedules Q2 Operating and Financial Results Webcast

Reuters
·
Aug 07

Lantern Pharma Spins Off Open-Medicine AI Platform

TIPRANKS
·
Aug 04

Lantern Pharma Spins Out Open-Medicine AI Unit to Commercialize Multi-Agent Drug Discovery Platform

Reuters
·
Aug 03

Lantern Pharma (Nasdaq: Ltrn) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine

THOMSON REUTERS
·
Aug 03

Lantern Pharma to advance EMA-cleared Phase 1b/2 trial of LP-184

TIPRANKS
·
Jul 28

Lantern Pharma Says EMA Clears Phase 1b/2 Lp-184 Bladder Cancer Trial

Reuters
·
Jul 28

Lantern Pharma to Advance Ema-Cleared Phase 1B/2 Trial of Lp-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer

THOMSON REUTERS
·
Jul 28

Lantern Pharma Says USPTO Allows Patent Application for Lp-184 Biomarker-guided Solid Tumor Treatment Methods

Reuters
·
Jul 23

Lantern Pharma Publishes Investor Presentation on Ai-driven Oncology Drug Development Platform, Pipeline Programs

Reuters
·
Jul 14

Lantern Pharma launches ZetaOmics computational-biology module

TIPRANKS
·
Jul 08